Current Hepatitis Reports

, Volume 11, Issue 4, pp 243–249

Clinical Implications of the Innate and Adaptive Immune Response to HBV and HCV

Global Perspectives: Australia (W Sievert, Section Editor)

Abstract

The tolerogenicity of the liver renders it vulnerable to hepatotrophic pathogens such as hepatitis B virus (HBV) and hepatitis C virus (HCV). Both viruses have successfully co-evolved within the human host by evading and counteracting immune control. Inadequate cell culture and animal models have limited definitive characterization of the immunological mechanisms arbitrating virus and host co-existence. The clinical sequelae of chronic viral hepatitis such as cirrhosis and hepatocellular carcinoma are not directly mediated by the viruses but rather by hepatotoxic immunological mediators and cytokines. The pro-fibrotic T helper 2 (Th2) response promoted by this altered cytokine milieu is associated with viral persistence. In this chapter, the innate and adaptive immune response to acute and chronic HBV and HCV is reviewed with particular focus on its clinical implications.

Keywords

Natural killer cells T lymphocytes Pattern recognition receptors TRAIL 

References

Papers of particular interest, published recently, have highlighted as: •• Of major importance

  1. 1.
    Racanelli V, Rehermann B. The Liver as an Immunological Organ. Hepatology. 2006;43:S54–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Saito T, et al. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature. 2008;454(7203):523–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee M, Kim Y-J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem. 2007;76:447–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Coudert JD, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood. 2005;106:1711–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Oppenheim DE, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol. 2005;6:928–37.PubMedCrossRefGoogle Scholar
  6. 6.
    Olviero B. Natural Killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology. 2009;137:1151–60.CrossRefGoogle Scholar
  7. 7.
    Dunn C, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology. 2009;137:1289–300.PubMedCrossRefGoogle Scholar
  8. 8.
    Wieland S, et al. Genomic analysis of early immune responses in patients with acute hepatitis B virus infection. Proc Natl Acad Sci U S A. 2004;101:66669–74.Google Scholar
  9. 9.
    Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2011. doi:10.1136/gutjnl-2011-301073. Epub ahead of print.
  10. 10.
    Fisicaro P, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut. 2009;58:974–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Boni C. Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection. J Virol. 2007;81(8):4215–25.PubMedCrossRefGoogle Scholar
  12. 12.
    Guidotti LG. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284:825–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006;1:23–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol. 2010;10(7):514–26. Review.PubMedCrossRefGoogle Scholar
  15. 15.
    Asabe S, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol. 2009;83:9652–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Yu S, et al. Hepatitis B virus polymerase inhibits RIG-1 and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol. 2010;91:2080–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Wei C, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol. 2010;185:1158–68.PubMedCrossRefGoogle Scholar
  18. 18.
    Visvanathan K, et al. Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology. 2007;45:102–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Tang TJ. The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat. 2003;10(3):159–67.PubMedCrossRefGoogle Scholar
  20. 20.
    Rehermann B, Hepatitis C. virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745–54.PubMedCrossRefGoogle Scholar
  21. 21.
    Shin EC et al. Virus-induced type 1 IFN stimulates generation of immunoprotesasomes at the site of infection. J Clin Invest. 116:3006–3014.Google Scholar
  22. 22.
    Kaplan DE et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology. 132:654–666Google Scholar
  23. 23.
    Urbani S, et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol. 2002;76:12423–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Decalf J, et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med. 2007;204:2423–37.PubMedCrossRefGoogle Scholar
  25. 25.
    Dolganiuc A, et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN- (alpha) and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol. 2006;177:6758–68.PubMedGoogle Scholar
  26. 26.
    Khakoo SI, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305:872–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Ochi M, et al. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology. 2004;39:1321–31.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang Z, et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology. 2011;53(3):730–85.Google Scholar
  29. 29.
    Dunn C, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007;204:667–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Zou Y, et al. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKGn ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol. 2010;184:466–75.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Jin Z, et al. Accelerated liver fibrosis in hepatitis b virus transgenic mice: involvement of natural killer T cells. Hepatology. 2011;53:219–29. This study showed that one of the potential immunopathogenic mechanisms contributing to liver fibrosis in HBV infection is through the induction of HSC activation by NKT cells.PubMedCrossRefGoogle Scholar
  32. 32.
    Yang G, et al. Association of CD4+ CD25+ Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol. 2007;19:133–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Tang Y, et al. Expression of CD39 on FoxP3+ T regulatory cells correlates with progression of HBV infection. BMC Immunol. 2012;13:17.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang J, et al. Interleukin-17 producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 2010;51:81–91.PubMedCrossRefGoogle Scholar
  35. 35.
    Zimmermann HW, et al. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One. 2011;6:e21381.PubMedCrossRefGoogle Scholar
  36. 36.
    Radziewicz H, et al. Impaired hepatitis C virus (HCV)-specific effector CD8 + T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver diuring the chronic phase of infection. J Virol. 2008;82:9808–22.PubMedCrossRefGoogle Scholar
  37. 37.
    Holz LE, et al. Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology. 2008;135:989–97.PubMedCrossRefGoogle Scholar
  38. 38.
    Soguero C, et al. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol. 2002;76(18):9345–54.PubMedCrossRefGoogle Scholar
  39. 39.
    Ahlenstiel G, et al. Natural Killer Cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology. 2010;138:325–35.PubMedCrossRefGoogle Scholar
  40. 40.
    Wang L. A longitudinal analysis of innate and adaptive immune profile during treatment with nucleos(t)ide analogs for chronic hepatitis B. J Hepatol. 2012;56:S225–388.CrossRefGoogle Scholar
  41. 41.
    Tjwa ET, et al. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol. 2011;54:209–18.PubMedCrossRefGoogle Scholar
  42. 42.
    Boni C, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol. 2003;39:595–605.PubMedCrossRefGoogle Scholar
  43. 43.
    Peppa D et al. Blockade of Immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 6(12):e1001227Google Scholar
  44. 44.
    Flink HJ. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy. Gut. 2005;54(11):1604–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Amarapurkar DN. Flares on and off therapy during chronic HBV infection: Pathogenesis, significance and management. Hep B Annual. 2008;5:12–22.CrossRefGoogle Scholar
  46. 46.
    Kafrouni MI, et al. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms. J Immunol. 2001;167:1566–74.PubMedGoogle Scholar
  47. 47.
    Tan AT, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol. 2010;52:330–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Chu C-M, Liaw Y-F. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010;15:133–43.PubMedCrossRefGoogle Scholar
  49. 49.
    •• Ahlenstiel G. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology. 2011;141:1231–9. This is the first study to examine NK cell activation in both peripheral blood and liver at a very early time point after treatment initiation. This study also demonstrated that the effect of exogenous IFN-α on NK cell activation and TRAIL expression occurs very early.PubMedCrossRefGoogle Scholar
  50. 50.
    Edlich B, et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of Hepatitic C patients. Hepatology. 2012;55:39–48.PubMedCrossRefGoogle Scholar
  51. 51.
    Suppiah V., et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: A cross-sectional study. PLoS Med 8(9):e1001092Google Scholar
  52. 52.
    Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of GastroenterologySouthern HealthClaytonAustralia
  2. 2.Department of Infectious DiseasesSouthern HealthClaytonAustralia
  3. 3.Department of MedicineMonash University (MMC)ClaytonAustralia
  4. 4.Department of Infectious DiseasesMonash Medical CentreClaytonAustralia

Personalised recommendations